Atherosclerosis is a multifactorial infl ammatory disease that can progress silently for decades and result in myocardial infarction, stroke, and death. Diagnostic imaging technologies have made great strides to defi ne the degree of atherosclerotic plaque burden through the severity of arterial stenosis. However, current technologies cannot differentiate more lethal "vulnerable plaques," and are not sensitive enough for preventive medicine. Imaging early molecular markers and quantifying the extent of disease progression continues to be a major challenge in the fi eld. 
Introduction
Atherosclerotic cardiovascular disease affects approximately 84 million American adults, leads to myocardial infarction and cerebral accidents, and accounts for more deaths than any other disease both in the US and worldwide. [ 1 ] Atherosclerosis is an infl ammatory disease characterized by heightened immunological activity and the build-up of lipid-rich plaques. The progression of atherosclerotic plaques is initiated by the accumulation of cholesterol particles within the artery wall. Subsequently, endothelial cells lining the wall undergo activation, which includes the secretion of monocyte chemoattractant protein-1 (MCP-1, also known as C C chemokine ligand 2), a chemokine which binds to the C C chemokine receptor, CCR2, found on the monocyte surface, recruiting them in large quantities. [ 2, 3 ] Monocytes differentiate into macrophages, ingesting and overloading on lipid particles, and thereby transform into foam cells. This results in amplifi cation of the local infl ammatory response, leads to further tissue injury through the secretion of more cytokines, chemokines, and toxic oxygen and nitrogen radicals, and precedes the formation of mature plaques, or atheromas, consisting of a lipid-rich, necrotic core surrounded by a fi brous cap. [ 4 ] Monocyte accumulation in the arterial wall is observed in fatty streaks, the earliest visible lesion of human and experimental atherosclerosis. In the ApoE knock-out mouse, the most commonly used and well-characterized animal model of atherosclerosis, monocyte accumulation is continuous and proportional to disease progression. [ 5 ] Furthermore, in the absence of monocyte migration, atherosclerosis development is greatly hindered. [ 6 ] In humans, the dynamics of accumulation is not as well understood, although rupture-prone plaques in patients also contain higher numbers of monocytes. [ 7 ] Targeting monocytes as a strategy to diagnose atherosclerosis could yield a molecular imaging tool that would detect the early onset of atherosclerosis, quantify the extent of plaque progression, and identify plaques most vulnerable to precipitous rupture and subsequent myocardial infarctions or strokes. Today, the main imaging technologies for atherosclerosis include intravascular ultrasound (IVUS), computed tomography (CT), positron emission tomography (PET), nuclear perfusion imaging, and magnetic resonance imaging (MRI). Although these imaging techniques have made great strides to assess the state of atherosclerotic plaques, poor sensitivity, limited accuracy and reproducibility, safety concerns, cost effi ciency, and the subjective interpretation of results has hindered their use. [ 8, 9 ] Perhaps the biggest drawback of these technologies is the difficulty in correlating physical traits such as fi brous cap thickness or % area of the necrotic core to the molecular state of a plaque.
While atherosclerosis is one of the leading causes of morbidity and mortality worldwide, atherosclerosis is underserved by the nanomaterials community. [ 10 ] In order to image atherosclerotic plaques effectively through the use of a molecular target, we have previously developed a clot-binding peptide amphiphile micelle (PAM). [ 11 ] Peptide amphiphiles (PAs) are a class of synthetic molecules in which a biologically active peptide "headgroup" is chemically linked to a hydrophobic "tail." [12] [13] [14] Under aqueous conditions, the PAs self-assemble into micelles in which the tails form the core, sequestered from water, and the peptides are displayed on the exterior as part of the corona. PAMs are advantageous because the corona provides a locally concentrated multivalent peptide display, which can potentiate binding to a target of interest. [ 14, 15 ] Furthermore, the nanometer size provides favorable pharmacokinetic properties as well as permeability into leaky vasculature that exists in developing disease pathologies in vivo . [ 16, 17 ] Moreover, monocytes enter plaques from the luminal side of the arterial wall, allowing for accessibility to intravenously delivered particles. In previous work, when the fi brin-targeting peptide, cysteine-arginine-glutamic acid-lysine-alanine (CREKA, previously identifi ed via in vivo phage display), was used as the headgroup, these PAMs localized to microthrombi residing within the shoulder portion of atherosclerotic plaques, a location most prone to rupture, within the well-known murine ApoE knock-out model of atherosclerosis. [ 11 ] While visualization of fi brin within plaques is a powerful diagnostic tool, the presence of clots represents a very advanced stage of atherosclerosis, limiting the nanoparticle system to detecting high-risk, far downstream developments of plaque instability and providing only a narrow window of opportunity for disease management for the patient. [ 18, 19 ] In order to address the challenge of enabling earlier detection of atherosclerotic plaques and intervene during the evolving pathology of plaque formation and vulnerability, we elected to engineer spherical, monocyte-targeting PAMs through the incorporation of the CCR2-binding motif of MCP-1 in this study. We tested the ability of MCP-1 PAMs to bind to monocytes in vitro, and evaluated their ability to target and differentiate between varying stages of atherosclerosis in the ApoE knock-out mouse after 24 h. Moreover, we evaluate the initial clearance and biodistribution properties, as well as toxicity of these novel PAMs.
Results

Design and Characterization of MCP-1 PAMs
To construct monocyte-targeting PAMs, the CCR2-binding motif (residues 13-35) of MCP-1, YNFTNRKISVQRLASYRRITSSK, was modifi ed by adding a cysteine residue to the N-terminus and was conjugated via a thioether linkage to 1,2-distearoyl-snglycero-3-phosphoethanolamine-N -[amino(polyethylene glycol)-2000] DSPE-PEG(2000)-maleimide ( Figure 1 A, Figure S1 , Supporting Information). Control, non-targeting PAMs were constructed by conjugating a scrambled sequence of the MCP-1 peptide to the hydrophobic tail. The physicochemical properties of the hydrophobic tails and the interactions between peptide headgroups specify the supramolecular geometry, and the interposition of PEG between cell-specifi c, targeting peptides and a distearoyl lipid tail favors formation of uniform, small spherical micelles optimal for intravascular injection. [ 11, 20 ] Furthermore, the incorporation of PEG enhances the clearance properties and lifetime of the micelles. [ 21 ] Fluorescently labeled micelles were constructed for imaging by mixing DSPE-PEG(2000)-Cy7 with either DSPE-PEG(2000)-MCP-1 or DSPE-PEG(2000)-scrambled in a 10:90 molar ratio. Cy7 was chosen as the fl uorophore to be incorporated into micelles because its excitation and emission wavelengths in the near-infrared range are optimal to achieve both deep tissue penetration and low auto-fl uorescence for in vivo imaging, and 10 mol% Cy7 maximizes the fl uorescence signal without quenching ( Figure S2 , Supporting Information). [ 22 ] The critical micelle concentrations (CMCs) of resulting MCP-1 and scrambled PAMs were determined to be 2.2 × 10 −6 and 1.6 × 10 −6 M , respectively, via the 1,6-diphenyl-1,3,5-hexatriene (DPH) fl uorescence assay [ 23 ] ( Table 1 ) , which are comparable to micellar systems composed of DSPE-PEG(2000). Transmission electron microscopy (TEM) and dynamic light scattering (DLS) confi rmed the presence of spherical micelles with an average diameter of 14.7 ± 1.4 and 13.1 ± 1.4 nm (Figure 1 B and Table 1 ). [ 20 ] Zeta potential measurements indicated that both MCP-1 and scrambled PAMs were positively charged (11.6 ± 0.1 and 10.9 ± 3.4 mV, respectively, Table 1 ); however, circular dichroism (CD) showed that the two peptides differed in secondary structure. The secondary structure of the free MCP-1 peptide sequences consisted of 34.2 ± 3.5% beta sheet, 65.8 ± 3.5% random coil, and 0.0 ± 0.0% alpha helix, while scrambled peptides consisted of 37.5 ± 6.2% beta sheet, 62.5 ± 6.2% random coil, and 0.0 ± 0.0% alpha helix (Table 1 ) . Upon micellization, the secondary structure was enhanced (MCP-1 PAMs: 45.9 ± 1.0% beta sheet, 53.4 ± 1.6% random coil, and 0.7 ± 0.7% alpha helix; scrambled PAMs consisted of 60.9 ± 2.9% beta sheet, 38.8 ± 2.3% random coil, and 0.3 ± 0.7% alpha helix, Table 1 ). The PEG spacer drives spherical micelle formation by swelling the corona, but does not promote peptide folding as strongly as tighter tethering does. Both peptide sequence and secondary structure contribute to the specifi c recognition of MCP-1 PAMs by the CCR2 receptor and the mode of interaction with the cell membrane. [ 14, 24 ] It may be possible to enhance this interaction further by further stabilization of a specifi c secondary structure, which we will examine in future work.
MCP-1 PAMs Bind to Monocytes and are Biocompatible I n Vitro
To verify the specifi city of Cy7-MCP-1 PAM binding with monocytes, the murine monocyte cell line WEHI-274.1 was used in vitro. Confocal fl uorescence microscopy showed specifi c binding of monocytes to Cy7-MCP-1 PAMs after 1 h, with little to no binding with the Cy7-scrambled PAM control ( Figure 2 A) . Inhibition of nonspecifi c uptake by phagocytic monocytes after 1 h may be attributable to PEG, which has been previously shown to shield particles from phagocytosis in the absence of a targeting peptide. [ 25 ] To test the eventual applicability for in vivo applications, biocompatibility of both MCP-1 and scrambled PAMs with WEHI-274.1 and primary murine aortic endothelial cells (mAECs) after a 24 h incubation was confi rmed using the Live/Dead cell viability assay (Figure 2 B) . Over 99% of both cell types were viable upon treatment with either micelle and were comparable to phosphate buffer saline (PBS)-treated samples ( Figure S3 , Supporting Information).
Detecting and Discriminating Various Stages of Atherosclerosis
Following in vitro studies, we investigated targeting of Cy7-MCP-1 PAMs to monocytes in vivo and determined the potential for Cy7-MCP-1 PAMs as a platform for atherosclerosis 
diagnostics upon intravenous administration in the murine ApoE knock-out model. As monocyte accumulation increases with disease progression in this model, we hypothesized that the amount of Cy7-MCP-1 PAM binding and the corresponding fl uorescence signal in the early and late stages of the disease would refl ect this phenomenon. [ 5 ] The concentration and volume of micelles utilized for in vivo studies were such that it remained above the CMC even upon injection in the total blood volume in circulation. [ 11, 26 ] Ex vivo imaging after 24 h in circulation confi rmed the specifi city of Cy7-MCP-1 PAMs to the aorta in comparison to control, Cy7-scrambled PAMs ( Figure 3 ). Quantitative comparisons supported the specifi city of Cy7-MCP-1 PAMs binding to aortas in both stages of atherosclerosis, as compared to Cy7-scrambled PAMs. Furthermore, the level of Cy7-MCP-1 PAM binding to aortas of advanced stages of the disease (5.3 × 10 7 ± 9.9 × 10 6 radiance (p/s/cm 2 /sr)) was signifi cantly higher than in the early stage (2.7 × 10 7 ± 5.7 × 10 6 radiance (p/s/cm 2 /sr), p ≤ 0.05 , Figure 3 B ). Approximately 0.06% and 0.16% of total MCP-1 PAMs injected accumulated within early-and late-stage atherosclerotic aortas, respectively. Histological examination of the aortic arch revealed Cy7-MCP-1 PAMs accumulated primarily on the luminal surface of the vessel wall in mice with early stage atherosclerosis and on plaques in mice with late stage atherosclerosis, which overlapped with CCR2 expression (Figure 3 C) . Mice treated with Cy7-scrambled PAMs displayed some background fl uorescence, but the signal did not colocalize with monocytes, as confi rmed via anti-CCR2 staining. This further substantiated the binding capabilities of Cy7-MCP-1 PAMs to monocytes in vivo and demonstrated the ability of Cy7-MCP-1 PAMs to differentiate between the stages of atherosclerosis for diagnostic applications.
Clearance, Biodistribution, and Safety of MCP-1 PAMs
In vivo imaging confi rmed Cy7-MCP-1 and Cy7-scrambled PAMs remained in the bloodstream after 24 h, indicated through a background level of fl uorescence present throughout the body, which is consistent with our recent fi ndings showing micelles are cleared from circulation after 7 d ( Figure 4 ). [ 27 ] High accumulation of either PAM was detected in the bladder and liver, organs part of renal clearance and the monocyte phagocytic system (MPS, also called the reticuloendothelial system or RES), respectively. To further confi rm partial elimination of micelles through renal clearance, urine was collected directly from the bladder and fl uorescence measured (Figure 4 B ). An increase in Cy7 intensity was found for all samples when compared to PBS-injected samples ( Figure 4 C shows the distribution of micelles within the heart, lung, liver, spleen, large intestines, kidney, and bladder and quantifi cation is provided in Figure S4 (Supporting Information). Both types of PAMs were present in the bladder and the kidney as expected, as well as the liver and the spleen. However, histopathological evaluation of major organs did not detect abnormal lesions, and no apparent signs of tissue or cellular damage were observed in mice injected with Cy7-MCP-1 or Cy7-scrambled PAMs ( Figure 5 ). Findings were comparable to organ structures obtained from mice injected with PBS.
In order to evaluate the potential cytotoxic effects of Cy7-MCP-1 or Cy7-scrambled PAMs on the two major organs of MPS, the liver and spleen, the activity of the apoptosis marker, caspase-3, was measured ( Figure 6 ). Caspase activity levels for all injected samples were comparable to that of PBS-treated animals. To assess liver function, liver tissue levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured (Figure 6 C,D) . For both biochemical parameters and all samples, no statistical differences were found in comparison to the PBS control, further confi rming initial micelle biocompatibility and safety. 
Discussion
Traditional imaging of atherosclerosis has focused on the % occlusion of the arterial lumen or the structure of plaque, and primarily provides anatomic and physiological information at relatively late stages of the disease. [ 28 ] Advances in the basic and clinical biology of atherosclerosis have identifi ed key infl ammatory processes that contribute to lesion initiation, progression, and complication, and the emerging fi eld of molecular imaging has harnessed this information to target specifi c biochemical markers for accurate, early diagnosis. [ 28, 29 ] Nanosized micelles are suitable for molecular and cellular level imaging tools as they are small enough to interact with receptor targets with high specifi city and avidity, owing to their multivalency, and provide high surface areas that can be decorated with targeting ligands and imaging agents to allow tracking of their distribution. [ 10 ] However, inspection and quantifi cation of disease advancement have been particularly challenging due to the complex nature of atherosclerosis, which is characterized by multiple silent events that can evolve over decades, some fatal without warning. As a result, treatment or management, especially at early stages of the disease, proves diffi cult. In contrast, we show that MCP-1 PAMs bind to the CCR2 receptor and accumulate in the aortic arch in proportion to disease progression in the ApoE knockout mouse, offering a tool to both diagnose and differentiate between the stages of atherosclerosis, which can be expanded to assess other sites of plaque formation including the carotid, subclavian, and iliac arteries (Figure 3 ) . [ 30 ] Consequently, MCP-1 PAM technology represents an important diagnostic paradigm for systemically targeting persistent markers of atherosclerosis that provide insight into the degree of vulnerability and therefore direct translation for specifi c and potentially personalized disease management regimens. It is important to note that although CCR2 is a well-known receptor on monocytes, activated endothelial cells have also been reported to express some CCR2 within plaques and may also be contributing to the targeting signal of MCP-1 PAMs in vivo . [ 31 ] Selectivity of MCP-1 PAMs for monocytes in vivo over other cell types encountered in the blood and vasculature will be further investigated in future studies.
Furthermore, the evaluation of tissue dissemination, clearance mechanisms, and toxicity is critical for preclinical assessment of diagnostic agents. Here, we show that PAMs are eliminated from the body via both renal clearance and MPS, causing no observable toxicity to organs involved 24 h post-circulation Data points are mean ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001, *** P < 0.0001 compared to the PBS-treated group. C) Ex vivo imaging of the heart, lung, liver, spleen, large intestines, kidney, and bladder treated with MCP-1 PAM, scrambled PAM, or PBS.
( Figure 4 ,5 , and 6 ). Based on the 15 nm size of our micelles, our results are consistent with our recent fi ndings and others who report nanoparticles >10 nm are cleared by the MPS, specifi cally through sequestration by sinusoids in the spleen and fenestra of the liver. [ 27 ] Particles <6 nm are distributed widely in a variety of organs by crossing tight endothelial junctions and are excreted through the renal system. [ 32 ] As our micelles are dynamic species, it is possible that upon reaching the targeting site, only some amphiphile monomers bind, in turn causing micelle disassembly and clearance of non-bound monomers through the bladder. After 7 d, approximately 90% of micelles are cleared out of the body. [ 27 ] In summary, we have combined a rational materials and biological approach to provide proof-of-concept that intravenously administered MCP-1 PAMs can target plaques and detect the extent of atherosclerosis in a mouse model. These nanoassemblies have the opportunity to advance atherosclerosis therapies by enhancing drug solubility through exploitation of the micelle's hydrophobic core, reducing the required dosage and potential for cytotoxicity via active targeting and focal delivery, increasing systemic circulation time of the carrier, and providing multifunctionality by combining therapeutic and diagnostic agents within one, theranostic system. Regarding additional imaging modalities, especially those that are clinically in use, modifi cations with radionuclides and contrast agents for PET and MRI such as copper 64 and gadolinium can be easily adapted into the modular design of micelles, providing enhanced spatial resolution with minimal interference from agents accumulated in other organs such as the liver. [ 33, 34 ] Moreover, these imaging modalities adapted for micelles could then be combined with anti-infl ammatory drugs for potential theranostic applications. In addition to micelles that target molecular or cellular markers, micelles can be further optimized to assess structural components of vulnerable plaques by imaging fi brous cap thickness and the area of the necrotic core via incorporation of collagen or metalloproteinase-binding peptides. [ 35 ] As monocytosis is characteristic to multiple infl ammatory diseases, MCP-1 PAMs also have the potential to be employed in multiple applications. [ 36 ] Although the full extent of monocyte accumulation has not been fully tested in humans, PAMs may serve as a tool for discovery science as well, validating cellular abundance during the complex etiology of atherosclerosis.
Conclusion
We have designed and synthesized a novel, self-assembling PAM for targeting monocytes. These spherical micelles bind to monocytes in vitro and are effective at targeting atherosclerotic plaques in the ApoE knock-out mouse model after 24 h in circulation. Moreover, this system can quantitatively discriminate between early and late stages of atherosclerosis and does not cause adverse effects to vital organs. As the accumulation of monocytes is linked to atherosclerosis progression, MCP-1 PAMs are a promising tool for both diagnostic and preventive medicine, and have the potential to be developed as theranostic systems for a variety of diseases where infl ammation is the underlying cause.
Experimental Section
Materials : Amino acids and solvents for peptide synthesis were purchased from Protein Technologies (Tucson, AZ). Wang resin was obtained from Anaspec (Fremont, CA). DSPE-PEG2000-maleimide and DSPE-PEG2000-amine were obtained from Avanti Polar Lipids (Alabaster, AL), Cyanine7 (Cy7) mono-N-hydroxysuccinimide ester from GE Healthcare Life Sciences (Pittsburgh, PA), and 400 mesh lacey carbon grids from Ted Pella (Redding, CA). mAECs, murine aortic smooth muscle cells (mASMCs), and M1168 or M2268 media were purchased from Cell Biologics (Chicago, IL). Mouse monocytes, WEHI-274.1, were purchased from ATCC (Manassas, VA) and Dulbecco's modifi ed Eagle's medium, fetal bovine serum, penicillin/streptomycin, and 2-mercaptoethanol from Sigma Aldrich (St. Louis, MO). The Live/ Dead assay kit was obtained from Molecular Probes (Eugene, OR). Mice with the Apoe tm1Unc mutation (The Jackson Laboratory, Bar Harbor, ME) Figure 5 . Representative H and E staining of the organs upon PAM administration . No morphological changes or tissue damage was demonstrated in the heart, lung, liver, spleen, large intestines, kidney, and bladder treated with MCP-1 PAM or scrambled PAM, compared to PBStreated controls.
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were fed a high-fat diet that consists of 21% (wt/wt) fat, 0.15% (wt/ wt) cholesterol, 19.5% (wt/wt) casein, and no sodium cholate (Harlan, Indianapolis, Indiana). The CCR2 primary antibody (ab32144) was purchased from Abcam (Cambridge, England). Biotinylated goat antirabbit IgG secondary antibody, Vectastain Elite ABC Kit, and Avidin/ Biotin Blocking Kit were obtained from Vector Laboratories (Burlingame, CA). OCT and DAB/DAB+ Chromogen Solution were purchased from Sakura Finetek (Torrance, CA) and DAKO (Darpinteria, CA), respectively. Fluorescence and colorimetric assay kits to measure ALT (MAK052), AST (MAK055), and caspase-3 activity (CASP3C) were derived from Sigma Aldrich (St. Louis, MO).
Micelle Synthesis : The CCR2-binding motif (residues 13-35) of the MCP-1 protein [YNFTNRKISVQRLASYRRITSSK] or scrambled peptide sequence [YNSLVFRIRNSTQRKYRASIST] was modifi ed by adding a cysteine residue to the N-terminus for covalent conjugation to the micelle lipid tail. The MCP-1 peptide (0.25 mmol) was synthesized using standard Fmoc-mediated solid-phase peptide synthesis methods on a Wang resin using an automated PS3 Benchtop Peptide Synthesizer (Protein Technologies, Tucson, AZ). Peptides were cleaved/deprotected with 94:2.5:2.5:1 vol% TFA:1,2-ethanedithiol:H2O:triisopropylsilane (TIS) and were precipitated and washed several times with cold diethyl ether, dissolved in water, lyophilized, and stored as lyophilized powders at -20 °C. Crude peptide mixtures were purifi ed by reverse-phase HPLC (Prominence, Shimadzu, Columbia, MD) on a C4 column (Waters, Milford, MA) at 55 °C using 0.1% trifl uoroacetic acid in acetonitrile/ water mixtures and characterized by MALDI-TOF/TOF mass spectral analysis (Bifl ex III, Bruker, Billerica, MA). Cysteine-containing peptides (10-15 mg) were conjugated via a thioether linkage to DSPE-PEG2000-maleimide by adding a 10% molar excess of the lipid to peptide in water (2-3 mL). After reaction at room temperature for 24 h, the resulting product was purifi ed and characterized as described above. The fi nal concentration of PA in solution was determined using amino acid analysis (Molecular Structure Facility, UC Davis, Davis, CA). Cy7 (5 mg) was conjugated via an amide bond to DSPE-PEG2000-amine by adding an equal molar equivalent of Cy7 mono-N-hydroxysuccinimide ester to the lipid dissolved in 10 × 10 −3 M aqueous sodium carbonate buffer (pH 8.5, 1-2 mL). After reaction at room temperature for 24 h, the mixture was also purifi ed and characterized as described above.
Fluorescently-labeled MCP-1 micelles were assembled by dissolving the Cy7 and peptide-containing DSPE-PEG(2000) amphiphiles in methanol, mixing the components, and evaporating the mixed solution under nitrogen. The resulting fi lm was dried under vacuum overnight, and then hydrated at 80 °C for 30 min in water or PBS and allowed to cool to room temperature.
Transmission Electron Microscopy : Negative staining samples for TEM were prepared by placing the 100 × 10 −6 M PAM solution on carbon grids for 2 min. Excess liquid was wicked away with fi lter paper and the grid was washed with Milli-Q water before placing 1 wt% phosphotungstic acid solution for 2 min and washing with Milli-Q water. Dried samples were imaged on a JEOL 1230 TEM, immediately (JEOL, Ltd., Tokyo, Japan).
Dynamic Light Scattering : Stock solutions of 100 × 10 −6 M PAM in PBS were used to confi rm the presence of small spheroidal micelles and DLS measurements were determined at 90° and 637 nm using a Brookhaven Instruments system (Holtzville, NY) consisting of a BI-200SM goniometer and a BI-9000AT autocorrelator ( N ≥ 3 samples).
Zeta Potential : Zeta potential was determined by measuring 100 × 10 −6 M DSPE-PEG(2000)-MCP-1 and DSPE-PEG(2000)-scrambled micelles dissolved in water (Zetasizer Nano ZS, Malvern, Worcestershire, United Kingdom, N ≥ 6).
Circular Dichroism Spectroscopy : CD spectroscopy was performed on a Jasco J-815 spectropolarimeter (Easton, MD). Peptide and PA solutions (100 × 10 −6 M ) were analyzed using 0.2 mm path-length cuvettes at room temperature and measurements were collected at 0.5 nm intervals from 265 to 190 nm with a 1 s averaging time and a 1 nm bandwidth. Five scans were collected and the data were averaged. To quantify secondary structure, the CD spectra were fi t by a linear combination of polylysine basis spectra. [ 37 ] 1,6-Diphenyl-1,3,5-hexatriene Fluorescence : The CMC was determined using DPH fl uorescence. [ 23 ] This method relies on an increase in DPH fl uorescence as it partitions from aqueous solution into the hydrophobic micelle core. Solutions of the MCP-1 and scrambled PA ranged in concentrations from 316 × 10 −6 to 0.01 × 10 −6 M . DPH was dissolved in tetrahydrofuran (THF) and a small amount of this solution was added to each PA solution to achieve 1 × 10 −6 M DPH with a residual THF volume percentage of approximately 0.1. Solutions containing both PA and DPH Cell Culture : mAECs were cultured and expanded following the manufacturer's instructions. Mouse monocytes (WEHI-274.1) were cultured and expanded in Dulbecco's modifi ed Eagle's medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 0.05 × 10 −3 M 2-mercaptoethanol. All cell types were cultured at 37 °C in a humidifi ed incubator under 5% CO 2 . Cells at passage fi ve were used and media were changed every 2-3 d.
Micelle Binding In Vitro : Cell uptake of mixed micelles containing DSPE-PEG(2000)-Cy7:DSPE-PEG(2000)-MCP-1 and DSPE-PEG(2000)-Cy7:DSPE-PEG(2000)-scrambled (10:90 molar ratio) was examined using confocal microscopy. Monocytes (50 000) were cultured in glass bottom dishes and incubated with mixed micelles at a fi nal concentration of 100 × 10 −6 M suspended in full media for 1 h at 37 °C in a humidifi ed incubator under 5% CO 2 . Live imaging was conducted on a Fluoview FV1200 laser scanning confocal microscope (Olympus, Center Valley, PA, N = 3).
In Vitro Biocompatibility : To assess biocompatibility, 10 000 mAEC or 50 000 monocytes were cultured within 96-well plates and after 24 h, 20 µL of PBS or 1 × 10 −3 M MCP-1 or scrambled PAMs were added to 180 µL of growth media (100 × 10 −6 M fi nal micelle concentration). After 24 h of incubation, cell viability was determined by a Live/Dead assay kit and imaged on a Leica DMI6000B fl uorescence microscope (Buffalo Grove, IL, N = 3).
Targeting of MCP-1 PAMs to Atherosclerotic Plaques : In order to conduct proof-of-concept experiments to test the hypothesis that MCP-1 PAMs can target monocytes in atherosclerotic plaques as well as discriminate the extent of disease progression, female, four-week old, transgenic mice homozygous for the Apoe tm1Unc mutation were fed a high-fat diet that consists of 21% (wt/wt) fat, 0.15% (wt/wt) cholesterol, 19.5% (wt/wt) casein, and no sodium cholate for 12 or 20-24 weeks to generate early-stage and late-stage lesions. [ 38, 39 ] Mice were shaved and naired, and tail veins were dilated and sterilized with 70% ethanol before 100 µL of 1 × N ≥ 3) . The control group consisted of mice with early-stage atherosclerosis treated with PBS alone, and all mice were chosen in random order and assigned randomly into each group by a third party. All mice were used for data collection. Micelles were allowed to circulate for 24 h before mice were anesthetized with 2.5% isofl urane in O 2 and whole body fl uorescence imaging was conducted (IVIS 200, Xenogen, Caliper Life Sciences, Hopkinton, MA, USA). Mice were then euthanized via CO 2 overdose and the aorta, heart, lung, liver, spleen, large intestines, kidney, and bladder harvested. Near-infrared fl uorescence imaging of organs was conducted using an IVIS 200 Imaging System (PerkinElmer, Downers Grove, IL). Urine samples were collected directly from the bladder, diluted 25x in PBS, and Cy7 intensity quantifi ed on a 96-well plate (ex. 746 nm, em. 776 nm, Infi nite 200 Pro, Tecan Group Ltd., Mannedorf, Switzerland) to assess clearance through the renal system. All animal procedures followed NIH guidelines for the care and use of laboratory animals and were approved by the University of Chicago's Institutional Animal Care and Use Committee (Chicago, IL).
Histology : Following optical imaging and euthanasia, the aorta, heart, lung, large intestines, liver, kidney, spleen, and bladder were fi xed with 4% paraformaldehyde overnight at 4 °C. Tissue was then submerged in a 30% sucrose solution for 8 h and frozen in OCT before 5-7 µm samples were cryosectioned (Microm HM 525, Fisher Scientifi c, Pittsburgh, PA), stained with hemotoxylin and eosin (H and E), and imaged (DMI6000 B, Leica Microsystems, Inc., Buffalo Grove, IL). Unstained and DAPI-stained cross-sections of the aortic arch were imaged for micelles (Cy7) and cell nuclei, respectively, on a fl uorescence microscope (DMI6000 B, Leica Microsystems, Inc., Buffalo Grove, IL). Representative images are presented.
Immunohistochemistry : Serial cross-sections (5-7 µm thick) of the aortic arch were mounted on silane-treated slides and allowed to air dry. Tissue sections were treated with 3% hydrogen peroxide, blocked with the Avidin/Biotin Blocking Kit, and 10% normal goat serum in TBS, and incubated with an antibody against CCR2 in a humidifi ed chamber at room temperature for 1 h (1:150) to visualize monocytes. Slides were washed with TBS and incubated with biotinylated goat anti-rabbit IgG secondary antibody for 1 h and Vectastain Elite ABC Kit for 30 min at room temperature. Sections were developed using the DAB/DAB+ Chromogen Solution and counterstained with Gill III Hematoxylin. All sections were dehydrated, mounted, and evaluated using bright-fi eld microscopy (DMI6000 B, Leica Microsystems, Inc., Buffalo Grove, IL). Representative images are presented.
Liver and Spleen Function : To assess liver function, an equal mass of tissue was homogenized in lysis buffer and liver levels of ALT and AST were measured using commercial assay kits. In addition, the level of apoptosis in the liver and spleen was determined by colorimetric quantifi cation of caspase-3 activity.
Statistical Analysis : Data are expressed as mean ± SEM. A Student's t -test was used to compare means of pairs and analysis of variance (ANOVA) using Tukey multiple comparison test post-hoc analysis to determine signifi cant differences among three or more means. A p value of 0.05 or less was considered to be signifi cant.
Supporting Information
Supporting Information is available from the Wiley Online Library or from the author.
